A case of multiple primary lung adenocarcinoma with a <scp>CD74‐NRG1</scp> fusion protein and <scp>HER2</scp> mutation benefit from combined target therapy-Reference-Cited by-同舟云学术

A case of multiple primary lung adenocarcinoma with a CD74‐NRG1 fusion protein and HER2 mutation benefit from combined target therapy

Published:2022-09-12 Issue:21 Volume:13 Page:3063-3067
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thoracic Cancer

Author:

Chen Kai¹,Li Wen¹,Xi Xiaoming¹,Zhong Jia²^ORCID

Affiliation:

1. Department of Oncology Beijing Chaoyang San Huan Cancer Hospital Beijing China

2. State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China

Funder

Beijing Municipal Natural Science Foundation

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.14636

Reference25 articles.

1. Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs

2. Molecular Pathways: Targeting NRG1 Fusions in Lung Cancer

3. Detection of NRG1 Gene Fusions in Solid Tumors

4. CD74–NRG1 Fusions in Lung Adenocarcinoma

5. Successful targeting of the NRG1 fusion reveals durable response to afatinib in lung adenocarcinoma: a case report

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Analysis of CD74 Occurrence in Oncogenic Fusion Proteins;International Journal of Molecular Sciences;2023-11-05

2. Analysis of rare fusions in NSCLC: Genomic architecture and clinical implications;Lung Cancer;2023-10

3. Antineoplastics;Reactions Weekly;2023-04-08